

Edgar Filing: EYE DYNAMICS INC - Form 10QSB

EYE DYNAMICS INC  
Form 10QSB  
August 14, 2002

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

Form 10-QSB

(X) Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended JUNE 30, 2002.

EYE DYNAMICS, INC.  
(Name of small business issuer in its charter)

Nevada 88-0249812  
(State or other jurisdiction (I.R.S. Employer Identification No.)  
of incorporation)

2301 W. 205th Street, #106, Torrance, CA 90501  
(Address of principal executive offices) (City, state and ZIP)

Issuer's telephone number 310-328-0477

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No []

The number of shares outstanding of the issuer's common stock as of June 30, 2002 was 17,050,313.

Transitional Small Business Disclosure Format (check one) ( ) Yes; (X) No.

PART 1 FINANCIAL INFORMATION

ITEM 1. Financial Statements

EYE DYNAMICS, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS (UNAUDITED)  
JUNE 30, 2002

-----

ASSETS

Current Assets		
Cash	\$	14,472
Account receivable		46,750

Edgar Filing: EYE DYNAMICS INC - Form 10QSB

Employee loans and advances	64,722
Inventory	145,286
	-----
TOTAL CURRENT ASSETS	302,253
Property and Equipment, net of accumulated depreciation of \$13,627	1,136
Other Assets	10,536
	-----
TOTAL ASSETS	\$ 313,925
	=====

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities	
Accounts payable & accrued expenses	\$ 69,571
Accrued interest	88,356
Line of Credit	59,621
Notes payable, current portion	8,000
	-----
TOTAL CURRENT LIABILITIES	225,548
Long-term debt	535,229
	-----
TOTAL LIABILITIES	760,777
Stockholders' Deficit	
Common Stock, \$0.001 par value; 50,000,000 shares authorized; 17,050,313 shares issued and outstanding	17,050
Paid-in capital	3,453,236
Accumulated deficit	(3,853,388)
Unamortized expenses (contra-equity)	(63,750)
	-----
	(446,852)
	-----
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$ 313,925
	=====

See Notes to Interim Unaudited Consolidated Financial Statements

1

EYE DYNAMICS, INC. & SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)  
For Three and Six Months ended June 30, 2002 and 2001

		For Three Months ended June 30,	For Six Months ended June 30,
		2002	2001
		2002	2001
-----		-----	-----
		2002	2001
-----		-----	-----

Edgar Filing: EYE DYNAMICS INC - Form 10QSB

Sales	\$ 311,894	\$ 162,648	\$ 529,581	\$ 274
Cost of sales	143,062	72,272	237,134	116
Gross profit	168,832	90,376	292,447	157
Selling, general and administrative expenses	173,046	231,760	337,670	488
(Loss) from operations	(4,214)	(141,384)	(45,223)	(330)
Other income (expenses)				
Interest and other income	1,627	1,485	3,112	1
Interest Expenses	(3,895)	(10,433)	(7,419)	(20)
Total other income (expenses)	(2,268)	(8,948)	(4,307)	(18)
Net (loss) before taxes and extraordinary item	(6,482)	(150,332)	(49,530)	(348)
Provision for income taxes	--	--	1,600	1
Net (loss) before extraordinary item	(6,482)	(150,332)	(51,130)	(350)
Extraordinary item-gain on restructuring of debt, net of applicable income taxes of \$0	26,479	--	26,579	
Net income (loss)	\$ 19,997	\$ (150,332)	\$ (24,651)	\$ 350
Per share of common stock				
Loss before extraordinary item	\$ (0.00)	\$ (0.01)	\$ (0.00)	\$ (
Extraordinary item, net	0.00	--	0.00	
Net income (loss) per share - basic and diluted	\$ 0.00	\$ (0.01)	\$ (0.00)	\$ (
Weighted average number of shares	16,216,980	12,025,313	15,350,313	11,858

See Notes to Interim Unaudited Consolidated Financial Statements

EYE DYNAMICS, INC. AND SUBSIDIARY  
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)  
For Six Months Ended June 30, 2002 and 2001

2002 2001

## Edgar Filing: EYE DYNAMICS INC - Form 10QSB

Cash Flows From Operating Activities		
Net (loss)	\$ (24,651)	\$ (350,068)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:		
Depreciation	739	1,305
Noncash expenses	102,307	144,306
Extraordinary gain on debt restructuring	(26,479)	--
(Increase) decrease in:		
Accounts receivable	4,805	59,157
Inventory	(29,769)	(57,918)
Prepays and other assets	(9,530)	4,652
Increase (decrease) in:		
Accounts payable and accrued expenses	15,668	27,250
Contingent liabilities	(75,000)	--
Accrued interest	(14,645)	18,732
	(56,555)	(152,584)
CASH FLOWS (USED IN) OPERATING ACTIVITIES		
Cash Flow From Investing Activities:		
Employee loans and advances	394	(50,516)
	394	(50,516)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES		
Cash Flow From Financing Activities:		
Proceeds from issuing of common stock	--	50,000
Advance from line of credit	14,260	54,378
Net proceeds from (repayments on) notes payable to shareholder	(15,000)	15,000
Net proceeds from other notes payable	47,750	10,250
	47,010	129,628
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		
NET (DECREASE) IN CASH	(9,151)	(73,472)
Cash balance at beginning of period	23,623	85,688
CASH BALANCE AT END OF PERIOD	\$ 14,472	\$ 12,216
Supplemental Disclosures of Cash Flow Information:		
Interest Paid	\$ 22,064	\$ 1,412
Taxes Paid	1,600	--
Supplemental Schedules of Noncash Investing and Financing Activities		
Issuing common stock for:		
Services	\$ --	\$ 177,226
Reduction of liability	10,000	21,000
Restructuring of debt	100,000	--

See Notes to Interim Unaudited Consolidated Financial Statements

## Edgar Filing: EYE DYNAMICS INC - Form 10QSB

NOTES TO INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS  
-----

### NOTE 1 - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

**NATURE OF BUSINESS:** Eye Dynamics, Inc. and subsidiary (the "Company") markets and distributes diagnostic equipment that utilize the Company's proprietary technology and computer software to test individuals for impaired eye and pupil performance. The Company also markets a medical diagnostic product that tracks and measures eye movements during a series of standardized tests.

A summary of significant accounting policies follows:

**PRESENTATION OF INTERIM INFORMATION:** In the opinion of the management, consisting only of normal recurring adjustments, necessary for a fair presentation of the financial condition and the results of operations of the Company for the periods presented have been included. Interim results are not necessarily indicative of results for a full year. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted unless significant changes have occurred since the Form 10-KSB was filed. The accompanying financial statements and notes thereto should be read in conjunction with the Company's Form 10-KSB.

**PRINCIPLES OF CONSOLIDATION AND PRESENTATION:** The accompanying consolidated financial statements include the accounts of Eye Dynamics, Inc. and its wholly-owned subsidiary, Oculokinetics, Inc., after elimination of all material intercompany accounts and transactions. Certain prior period balances have been reclassified to conform to the current period presentation.

**DEBT RESTRUCTURINGS:** The Company accounts for debt restructurings that occurred in April 2002 in accordance with SFAS No. 15, "Accounting for Debtors and Creditors for Troubled Debt Restructurings." The statement requires that a debtor should (a) recognize a gain or loss by reducing the carrying amount of the debt by the fair value of the assets or equity interest transferred, and (b) account for the remainder of the restructuring as a modification of debt terms. When the terms of a debt are adjusted in a trouble-debt restructuring, the total amount of the future cash payments should be determined. If the carrying amount of debt is less than the aggregate future cash payments required by the new debt term, the debtor should amortize the difference over the life of the new debt as interest expense using the effective interest method. No gain or loss is recognized in the period of extinguishments. If the carrying amount of debt is greater than the aggregate future cash payments required by the new debt term, the debtor should reduce the carrying value of debt to an amount equal to the total future cash payments and recognize the reduction an extraordinary gain. No interest expense should be recorded.

**NEW ACCOUNTING STANDARDS:** SFAS No. 143, "Accounting for Asset Retirement Obligations," addresses financial accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs. The statement requires that the fair value of a liability for an asset retirement obligation be recognized in the period it is incurred if a reasonable estimate of fair value can be made. The associated retirement costs are capitalized as a component of the carrying amount of the long-lived asset and allocated to expense over the useful life of the asset. The statement is effective for financial statements issued for fiscal years beginning after June 15, 2002. Management believes the adoption of the statement will not have a material effect on the Company's financial statements.

# Edgar Filing: EYE DYNAMICS INC - Form 10QSB

EYE DYNAMICS, INC. AND SUBSIDIARY

NOTES TO INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

-----

## NOTE 1 - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

In August 2001, SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," was issued and establishes accounting and reporting standards for the impairment or disposal of long-lived assets. This statement supersedes SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed." SFAS No. 144 provides one accounting model to be used for long-lived assets to be disposed of by sale, whether previously held for use or newly acquired and broadens the presentation of discontinued operations to include more disposal transactions. The provisions of SFAS No. 144 are effective for financial statements issued for fiscal years beginning after December 15, 2001. Accordingly, the statement was effective for the Company for the fiscal quarter beginning January 1, 2002 and it did not have an impact on its financial position.

## NOTE 2 - DEBT RESTRUCTURING

In April 2002, the Company restructured a debt of \$396,721 plus accrued interest of \$223,987 with a prior distributor in regards to the Settlement Agreement and Mutual Release that was signed in 1993. The new settlement includes that a new note of \$400,000 was issued to replace the old debt. The new note is compounded at 7% per annum and is amortized over 5 years commencing January 1, 2003. The Company also paid a sum of \$60,000 in cash and issued 2,500,000 shares of restricted common stock to the prior distributor upon the execution of the new amendment. The fair market value of the stock at the date of settlement was \$0.04 per share. All accrued and unpaid interest on the old debt, and all amounts due related to the consigned inventory were forgiven. The Company recognized an extraordinary gain of \$26,479 on the restructuring in accordance with SFAS No. 15.

Debt carrying value:	
Original carrying amount of debt	\$ 396,721
Accrued and unpaid interest balance	223,987
Consigned inventory	41,000
	-----
Total debt	\$ 661,708
Less: fair value of consideration given:	
Cash paid	(60,000)
Common stock issued (2,500,000 shares at a fair value of \$0.04 per share)	(100,000)
	-----
	(160,000)
	-----
Carrying value of debt	501,708
Future cash flows:	
New debt principal	400,000
Interest to be paid on new principal amount	75,229
	-----
Total future cash payments required	475,229
	-----
Extraordinary gain recognized	\$ 26,479
	=====

# Edgar Filing: EYE DYNAMICS INC - Form 10QSB

5

EYE DYNAMICS, INC. AND SUBSIDIARY

NOTES TO INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

---

## NOTE 3 - NOTES PAYABLE

In May 2002, the Company issued two notes payable of \$40,000 and \$20,000 to fund the cash payment of \$60,000 as discussed in Note 2. Both notes carry an interest rate of 7% per annum commencing January 1, 2003. Principal and interest payable are due on December 31, 2007. The notes are convertible into 3,591,800 and 1,795,900 shares of the Company's restricted common stock, respectively. The notes are also callable on or before December 31, 2002 by the Company in the sum of \$13,333 and \$6,666, respectively. Upon the occurrence of such payments, the balance of the notes shall be convertible into 2,394,533 and 1,197,267 shares, respectively. The Company will also issue 266,667 and 133,333 shares of warrants, respectively, to the holders if such payments are made. The warrants are exercisable at five cents(\$0.05) per share and expire on December 31, 2007.

## NOTE 4 - LITIGATION SETTLEMENT

In 2001, the Company was involved in a lawsuit filed by 6800 Owensmouth, Inc. ("OWEN") alleging that the Company had aided and abetted an employee in avoiding payment of a lawsuit judgment in favor of OWEN. On February 21, 2002, the Board of Directors, in the interest of capital conservation and avoiding the time and expense of a court trial, approved to reach a settlement through a mediation conference. The settlement reached included payment of \$10,000 and issuance of 200,000 shares of 144 restricted common stock of the Company at a fair market value of \$0.05 per share. The settlement loss, aggregate of \$20,000, was accrued and charged to operations in 2001. The liability was paid in full and the shares were issued in February 2002.

## NOTE 5 - NONCASH FINANCING ACTIVITIES

In May 2002, the Company issued 2,500,000 shares of restricted common stock at a fair value of \$0.04 per share to restructure a debt (see Note 3).

In February 2002, the Company issued 200,000 shares of restricted common stock to reduce a contingent liability of \$10,000 which was accrued in 2001 (see Note 4).

## NOTE 6 - NET LOSS PER SHARE

Net loss per share is computed based on the weighted average number of shares of common stock outstanding during the period. Basic net loss per share was \$0.00 and \$0.01 for three months ended June 30, 2002 and 2001, respectively, and was \$0.00 and \$0.03 for six months ended June 30, 2002 and 2001, respectively. Net loss per share does not include options and warrants as they would be anti-dilutive in 2002 and 2001 due to the net loss in those periods.

6

## Edgar Filing: EYE DYNAMICS INC - Form 10QSB

EYE DYNAMICS, INC. AND SUBSIDIARY

NOTES TO INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

### NOTE 6 - NET LOSS PER SHARE (CONTINUED)

	Three Months ended June 30,		Six Months ended June 30,	
	2002	2001	2002	2001
Numerator:				
Net income (Loss)	\$ 19,997	\$ (150,332)	\$ (24,651)	\$ (350,068)
Denominator:				
Weighted average of common shares	16,216,980	12,025,313	15,350,313	11,858,313
Basic and diluted net loss per share	\$ 0.00	\$ (0.01)	\$ (0.00)	\$ (0.03)

The net income amount for three months ended June 30, 2002 and the net loss amount for six months ended June 30, 2002 included an after-tax amount of \$26,479, which relates primarily to an extraordinary gain from restructuring of debt. Excluding the effects of these transactions, the basic and diluted loss per share would have been the same for both periods.

### NOTE 7 - SEGMENT INFORMATION

SFAS No. 131 "Disclosures about Segments of an Enterprise and Related Information" requires that a publicly traded company must disclose information about its operating segments when it presents a complete set of financial statements. Since the subsidiary did not have any operations in 2002 or 2001, and the Company has only one segment; accordingly, detailed information of the reportable segment is not presented.

### NOTE 8 - GOING CONCERN

As shown in the accompanying consolidated financial statements, the Company incurred a net loss before extraordinary item of \$51,130 and \$350,068 for six months ended June 30, 2002 and 2001, respectively, and as of June 30, 2002, the Company's total liabilities exceeded its total assets by \$446,852. Those factors create uncertainty about the Company's ability to continue as a going concern.

As discussed in Note 2, the Company reduced its current liabilities by restructuring a default note payable of \$396,721 plus accrued interest of \$223,987 into a new long-term debt of \$400,000. The new debt is amortized at 7% per annum over 5 years commencing January 1, 2003.

The Company is also beginning to market and publicize its second product line, Impairment Detection Device. The Company continued existence depends on its ability to meet its financing requirements and the success of its future operations. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.



ITEM 2. Management's Discussion and Analysis or Plan of Operation

Revenues from the sale of medical products during the second quarter were \$312,000, representing a 91% increase over the first quarter of 2001. Revenues for the first half of 2002 were \$530,000, compared with \$275,000 for the first half of 2001, for a year to date increase of 92%. This increase can be attributed principally to the success of our private label customer opening up and developing new markets and applications for our video ENG products. As reported in the first quarter, the market increase in the ENT segment of the medical market is not substantial, but our penetration of the neurology segment, which our private label customer is pursuing, has been successful. We continue to receive additional interest from the export markets, and received orders from Korea and Iran during the period. Before we can fulfill orders from Iran, we must receive an export license from the U.S. government. While medical equipment and supplies qualify for export licenses, the government has been withholding licenses for the past several months and is processing them very slowly. We have enlisted the aid of our representative in Congress to assist in getting an export license approved.

Gross profit for the quarter was 55%, and 56% for the first six months of 2002. This figure is within 2% of the gross profit for the same period of 2001, and is a reflection of the increase in private label orders that we have been shipping, which have a lower gross profit structure.

We are continuing our efforts to secure financing for the business plan to commercialize the SafetyScope product, which is an Impairment Detection Device. The plan requires substantial financial resources to fully implement the commercialization of the product. Discussions and explorations of strategic alliances are ongoing with the goal of securing the financing.

We also completed restructuring an obligation of \$396,721, plus accrued interest of \$223,987, with a former distributor. The restructured obligation includes a new note for \$400,000, bearing interest at 7% per annum, with payments to commence in January, 2003. The note is amortized over five years, all due and payable in January 2008. In addition, we paid \$60,000 in cash and issued 2,500,000 shares of restricted common stock to the noteholder, in cancellation of all accrued and unpaid interest on the old debt. In addition, all amounts due related to consigned inventory were forgiven. The net of this transaction is that the company recognized an extraordinary gain of \$26,479 on the restructuring in accordance with SFAS No. 15. Further details of the restructuring are included in the Financial Statements, Note No. 2 - Debt restructuring.

As a result of the sales increase of 91% for the quarter, gross profit is substantially higher. When combined with the extraordinary gain of \$26,479 in debt restructuring, a net profit of \$19,997 was achieved for the quarter. This net income includes \$43,250 of expenses incurred in the promotion of the business plan for commercialization of the SafetyScope product. Without the SafetyScope commercialization expenses, the medical product sales and debt restructuring would have generated a substantial profit for the quarter. Net loss for the first half of 2002 was reduced to \$24,651, compared to a loss of \$350,068 for the first half of 2001, representing a substantial improvement.

Inventory of \$145,000 at June 30, 2002 includes \$41,000 of previously consigned inventory that was returned to us as a result of the restructuring of debt with a prior distributor. This inventory consists of Impairment Detection Devices and is being used as production samples and demonstrators for the fund raising activity related to the SafetyScope impairment detection device. The inventory balance of \$104,000 represents less than 60 days inventory for the medical products production and is balanced, except for the caloric irrigators which must be ordered from Germany and The Netherlands well in advance of needs. This tends to increase the inventory investment because of the long term delivery and pre-payment requirements for these imported items.

Accounts receivable of \$78,000 reflect less than 30 days average accounts outstanding. This favorable collection experience is principally due to the fact that our private label customer continues to make their payments within the terms of sale of net 15 days. Cash on hand at June 30, 2002 was \$14,472.

We continue to search out and evaluate other products and alliances to enhance the company and to augment our revenues. However, none are currently in the offing that we have found suitable. The search for new products is an ongoing project.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There are no pending legal proceedings to which the Company is a party or to which the property interests of the Company are subject.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

During the second quarter we issued 2,500,000 shares of restricted common stock to TESA Corporation as a part of the debt restructuring discussed above. The Company believes the issuance was exempt from registration under Section 4(2) of the Securities Act of 1933, as amended.

ITEM 3. DEFAULTS UPON SENIOR SECURITES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted to the vote of security holders during this quarterly reporting period.

ITEM 5 OTHER INFORMATION

The company completed negotiations to restructure an obligation of \$396,721, plus accrued interest of \$223,987, with a former distributor pursuant to a Settlement Agreement and Mutual Release that was signed in 1993. The new settlement includes a new note of \$400,000, which was issued to replace the old debt. The new note bears interest at 7% per annum and is amortized over five

## Edgar Filing: EYE DYNAMICS INC - Form 10QSB

years commencing January 1, 2003. The company also paid \$60,000 in cash and issued 2,500,000 shares of restricted common stock to the former distributor upon the execution of the new amendment. All accrued and unpaid interest on the old debt, and all amounts related to the consigned inventory, were forgiven.

### ITEM 6 EXHIBITS AND REPORTS ON FORM 8-K

(A) The following exhibits are included herein or incorporated by reference:

99.1 Certification of Chief Executive and Financial Officer.

(B) No reports on Form 8-K were filed during the period

### SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Eye Dynamics, Inc.

Date: August 13, 2002

By /s/ Charles E. Phillips

-----  
Charles E. Phillips, President  
and Chief Financial Officer